CELG:NSD-Celgene Corporation (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 108.24

Change

0.00 (0.00)%

Market Cap

USD 77.04B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


CELG Stock Forecast & Price:
Based on the Celgene Corporation stock forecasts from 0 analysts, the average analyst target price for Celgene Corporation is not available over the next 12 months. Celgene Corporation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Celgene Corporation is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Celgene Corporation’s stock price was USD 108.24. Celgene Corporation’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Celgene Corporation
No recent average analyst rating found for Celgene Corporation

About Celgene Corporation (CELG:NSD)

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and m ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-09-24 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC ADR

N/A

USD177.38B 1,689.87 28.71
AMGN Amgen Inc

N/A

USD121.83B 19.37 12.47
SNY Sanofi ADR

N/A

USD98.46B 14.71 11.24
GILD Gilead Sciences Inc

N/A

USD82.50B 20.13 11.92
BIIB Biogen Inc

N/A

USD29.11B 14.69 10.37
HZNP Horizon Pharma PLC

N/A

USD14.44B 19.70 12.31
GWPH GW Pharmaceuticals plc

N/A

USD6.81B 91.14 84.16
GRFS Grifols SA ADR

N/A

USD6.62B 76.95 17.45
TSVTV 2seventy bio Inc. Common Stock..

N/A

USD0.62B N/A N/A
CRXT Clarus Therapeutics Holdings I..

N/A

USD2.47M N/A -1.04

ETFs Containing CELG

Symbol Name Weight Mer Price(Change) Market Cap
OSXC:XETRA Ossiam Risk Weighted Enha.. 0.00 % 0.45 %

N/A

USD9.94M

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -25.32% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.32% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 4.93% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.93% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.81% N/A N/A N/A N/A
Risk Adjusted Return 27.66% N/A N/A N/A N/A
Market Capitalization 77.04B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 13.33 N/A N/A N/A N/A
Price/Book Ratio 6.37 N/A N/A N/A N/A
Price / Cash Flow Ratio 14.90 N/A N/A N/A N/A
EV/EBITDA 10.62 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 69.39% N/A N/A N/A N/A
Return on Invested Capital 13.89% N/A N/A N/A N/A
Return on Assets 13.69% N/A N/A N/A N/A
Debt to Equity Ratio 320.87% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 3.45 N/A N/A N/A N/A
Short Percent 1.85% N/A N/A N/A N/A
Beta 1.41 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike